Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 32

1.

Rapid Multiplexed Immunoassay for Detection of Antibodies to Kaposi's Sarcoma-Associated Herpesvirus.

Logan C, Todorof K, Fiorillo SP, Campbell TB, Elder JH, Borok M, Gudza I, Gwanzura L, Ndemera B, Lochhead MJ, Benson CA, Schooley RT.

PLoS One. 2016 Sep 26;11(9):e0163616. doi: 10.1371/journal.pone.0163616. eCollection 2016.

2.

HIV and human herpesvirus 8 co-infection across the globe: Systematic review and meta-analysis.

Rohner E, Wyss N, Heg Z, Faralli Z, Mbulaiteye SM, Novak U, Zwahlen M, Egger M, Bohlius J.

Int J Cancer. 2016 Jan 1;138(1):45-54. doi: 10.1002/ijc.29687. Epub 2015 Jul 28. Review.

3.

HHV-8 seroprevalence: a global view.

Rohner E, Wyss N, Trelle S, Mbulaiteye SM, Egger M, Novak U, Zwahlen M, Bohlius J.

Syst Rev. 2014 Feb 12;3:11. doi: 10.1186/2046-4053-3-11. Review.

4.

Population-based assessment of kaposi sarcoma-associated herpesvirus DNA in plasma among Ugandans.

Shebl FM, Emmanuel B, Bunts L, Biryahwaho B, Kiruthu C, Huang ML, Pfeiffer RM, Casper C, Mbulaiteye SM.

J Med Virol. 2013 Sep;85(9):1602-10. doi: 10.1002/jmv.23613.

5.

Professional antigen presenting cells in human herpesvirus 8 infection.

Knowlton ER, Lepone LM, Li J, Rappocciolo G, Jenkins FJ, Rinaldo CR.

Front Immunol. 2013 Jan 21;3:427. doi: 10.3389/fimmu.2012.00427. eCollection 2012.

6.

A population-based study of Kaposi Sarcoma-associated herpesvirus seropositivity in Uganda using principal components analysis.

Chang JT, Shebl FM, Pfeiffer RM, Biryahwaho B, Graubard BI, Mbulaiteye SM.

Infect Agent Cancer. 2013 Jan 16;8(1):3. doi: 10.1186/1750-9378-8-3.

7.

Pathology of Kaposi's Sarcoma-Associated Herpesvirus Infection.

Fukumoto H, Kanno T, Hasegawa H, Katano H.

Front Microbiol. 2011 Aug 25;2:175. doi: 10.3389/fmicb.2011.00175. eCollection 2011.

8.

Human herpesvirus 8 seropositivity among sexually active adults in Uganda.

Shebl FM, Dollard SC, Pfeiffer RM, Biryahwaho B, Amin MM, Munuo SS, Hladik W, Parsons R, Graubard BI, Mbulaiteye SM.

PLoS One. 2011;6(6):e21286. doi: 10.1371/journal.pone.0021286. Epub 2011 Jun 21.

9.

Risk factors influencing antibody responses to Kaposi's sarcoma-associated herpesvirus latent and lytic antigens in patients under antiretroviral therapy.

Guadalupe M, Pollock BH, Westbrook S, Redding S, Bullock D, Anstead G, Agan BK, Marconi VC, Barbieri S, Sankar V, Rebeles J, Flahive Y, Schoolfield J, Wang L, Lei X, Dow D, Yeh CK, Dang H, Infante AJ, Gao SJ.

J Acquir Immune Defic Syndr. 2011 Jan 1;56(1):83-90. doi: 10.1097/QAI.0b013e3181fdc928.

10.

Sex and geographic patterns of human herpesvirus 8 infection in a nationally representative population‐based sample in Uganda.

Biryahwaho B, Dollard SC, Pfeiffer RM, Shebl FM, Munuo S, Amin MM, Hladik W, Parsons R, Mbulaiteye SM.

J Infect Dis. 2010 Nov 1;202(9):1347-53. doi: 10.1086/656525.

11.

Detection of antibodies to Kaposi's sarcoma-associated herpesvirus: a new approach using K8.1 ELISA and a newly developed recombinant LANA ELISA.

Mbisa GL, Miley W, Gamache CJ, Gillette WK, Esposito D, Hopkins R, Busch MP, Schreiber GB, Little RF, Yarchoan R, Ortiz-Conde BA, Labò N, Whitby D.

J Immunol Methods. 2010 Apr 30;356(1-2):39-46. doi: 10.1016/j.jim.2010.02.015. Epub 2010 Mar 4.

12.

Kaposi sarcoma-associated herpesvirus (KSHV) seroprevalence in population-based samples of African children: evidence for at least 2 patterns of KSHV transmission.

Butler LM, Dorsey G, Hladik W, Rosenthal PJ, Brander C, Neilands TB, Mbisa G, Whitby D, Kiepiela P, Mosam A, Mzolo S, Dollard SC, Martin JN.

J Infect Dis. 2009 Aug 1;200(3):430-8. doi: 10.1086/600103.

13.

Four-antigen mixture containing v-cyclin for serological screening of human herpesvirus 8 infection.

Burbelo PD, Leahy HP, Groot S, Bishop LR, Miley W, Iadarola MJ, Whitby D, Kovacs JA.

Clin Vaccine Immunol. 2009 May;16(5):621-7. doi: 10.1128/CVI.00474-08. Epub 2009 Mar 4.

14.

Development of an immunofluorescence assay using recombinant proteins expressed in insect cells to screen and confirm presence of human herpesvirus 8-specific antibodies.

Minhas V, Crosby LN, Crabtree KL, Phiri S, M'soka TJ, Kankasa C, Harrington WJ, Mitchell CD, Wood C.

Clin Vaccine Immunol. 2008 Aug;15(8):1259-64. doi: 10.1128/CVI.00487-07. Epub 2008 May 28.

15.

Sexual activity and Kaposi's sarcoma among human immunodeficiency virus type 1 and human herpesvirus type 8-coinfected men.

Nawar EW, Cole SR, Farzadegan H, Witt MD, Jenkins FJ, Margolick JB, Phair JP, Jacobson LP.

Ann Epidemiol. 2008 Jul;18(7):517-21. doi: 10.1016/j.annepidem.2008.03.009. Epub 2008 May 27.

16.

Seroprevalence and risk factors for human herpesvirus 8 infection, rural Egypt.

Mbulaiteye SM, Pfeiffer RM, Dolan B, Tsang VC, Noh J, Mikhail NN, Abdel-Hamid M, Hashem M, Whitby D, Thomas Strickland G, Goedert JJ.

Emerg Infect Dis. 2008 Apr;14(4):586-91. doi: 10.3201/eid1404.070935.

17.

The viral etiology of AIDS-associated malignancies.

Angeletti PC, Zhang L, Wood C.

Adv Pharmacol. 2008;56:509-57. Review. No abstract available.

18.

Comparative study of Kaposi's sarcoma-associated herpesvirus serological assays using clinically and serologically defined reference standards and latent class analysis.

Nascimento MC, de Souza VA, Sumita LM, Freire W, Munoz F, Kim J, Pannuti CS, Mayaud P.

J Clin Microbiol. 2007 Mar;45(3):715-20. Epub 2006 Dec 20.

19.

Human herpesvirus 8--a novel human pathogen.

Edelman DC.

Virol J. 2005 Sep 2;2:78. Review.

Supplemental Content

Support Center